Insider Trading June 26, 2026 07:09 PM

Omada Health CFO Steven Cook Offloads $55,145 in Shares Under Pre-Arranged Plan

Executive divestment occurs amid recent price appreciation and positive earnings surprise, though valuation metrics suggest caution for the digital health provider.

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
OMDA

Steven L. Cook, Chief Financial Officer of Omada Health, Inc. (NASDAQ:OMDA), executed a series of stock sales totaling $55,145 over two days in late June 2026. The transactions, conducted under a 10b5-1 trading plan established in March, reduced his direct holdings to 166,359 shares. This activity follows a period of significant market movement for OMDA, which saw its stock price climb to $20.89, an 18% gain over the past week, despite internal assessments indicating the stock may be overvalued relative to its fair value. The sales coincide with the company's recent Q1 2026 earnings report, which demonstrated strong revenue growth and an earnings per share beat, alongside an upgrade in analyst price targets by Citizens.

Omada Health CFO Steven Cook Offloads $55,145 in Shares Under Pre-Arranged Plan
OMDA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CFO Steven Cook sold 2,900 shares totaling $55,145 under a 10b5-1 plan, leaving him with 166,359 direct shares.
  • OMDA stock surged 18% to $20.89 in the past week, though valuation metrics suggest the stock is currently overvalued relative to fair value.
  • Omada Health reported Q1 2026 revenue of $78 million, a 42% year-over-year increase, and beat EPS expectations, prompting Citizens to raise its price target to $21.

Steven L. Cook, the Chief Financial Officer of Omada Health, Inc. (NASDAQ:OMDA), has completed a series of equity transactions that resulted in the sale of company stock valued at $55,145. According to a Form 4 filing submitted to the Securities and Exchange Commission, the divestment activity occurred over a two-day period in late June 2026. The total volume of shares disposed of during this window amounted to 2,900 units.

The initial phase of the transaction took place on June 24, 2026, when Mr. Cook sold 2,600 shares of Omada Health common stock. The execution of these trades occurred within a narrow price band, with individual transactions ranging from $19.00 to $19.04. The weighted average price for this specific batch was recorded at $19.0173 per share. The following day, June 25, 2026, Mr. Cook completed the remainder of the disposal by selling an additional 300 shares. These final shares were transacted at a weighted average price of $19.0033, with individual trade prices falling between $19.00 and $19.01. The combined proceeds from these sales ranged between $19.0033 and $19.0173 per share.

Both sets of transactions were executed in accordance with a 10b5-1 trading plan that Mr. Cook adopted on March 14, 2026. This pre-arranged framework is typically utilized to facilitate the sale of company stock in a manner that avoids potential conflicts of interest or allegations of insider trading. Following the completion of these sales, Mr. Cook's direct ownership stake in Omada Health stands at 166,359 shares.

The executive divestment comes against a backdrop of notable market activity for Omada Health. The company's stock price has since climbed to $20.89, marking an 18% gain over the past week. Despite this recent upward momentum, analysis provided by InvestingPro suggests that the stock remains overvalued when measured against its calculated Fair Value. The firm maintains a robust balance sheet structure, holding more cash than debt, and reports a strong gross profit margin of 66%. Furthermore, analysts project that Omada Health is positioned to achieve profitability in the current year, supported by revenue growth of 49% over the last twelve months.

In related corporate developments, Omada Health recently reported its financial results for the first quarter of 2026. The company delivered an earnings per share (EPS) of -$0.05, which outperformed the consensus expectation of -$0.08. Revenue for the quarter reached $78 million, representing a 42% increase compared to the previous year. In response to these results, Citizens raised its price target for Omada Health from $18 to $21, while maintaining a Market Outperform rating. Analyst Constantine Davides noted that Omada Health was trading at 2.5 times the firm's 2026 revenue estimate.

On the governance front, the company held its 2026 Annual Meeting of Stockholders, where Sean Duffy and Trevor Fetter were elected as Class I Directors. Both individuals are set to serve until the 2029 annual meeting. These recent events highlight a period of active strategic and operational movement for the digital health provider.

Risks

  • Analyst analysis indicates the stock is overvalued relative to its Fair Value, suggesting a potential correction risk despite recent gains.
  • The company remains unprofitable with a Q1 2026 EPS of -$0.05, highlighting ongoing challenges in achieving sustained profitability.
  • Trading at 2.5 times the 2026 revenue estimate implies a premium valuation that may be sensitive to future growth disappointments.

More from Insider Trading

CoreWeave CSO Brian Venturo Executes $7.79 Million Stock Sale Under Pre-Arranged Plan Jun 26, 2026 Cadrenal Therapeutics CEO Sells Shares Amid Regulatory Milestones and Clinical Developments Jun 26, 2026 Clear Secure Executive Offloads $1.82M in Shares Amid Operational Expansion Jun 26, 2026 Clear Secure Director Alclear Investments Executes Rule 10b5-1 Share Sale Amid Valuation Metrics Jun 26, 2026 Personalis CFO Tachibana Executes $675K Stock Sale Under Pre-Approved Plan Jun 26, 2026